Machine learning and cox model–based prediction of CDK4/6 inhibitor outcomes in HR+/HER2 − metastatic breast cancer: a multicenter real-world study

Breast Cancer Research and Treatment · Published 2026-07-31 · DOI 10.1007/s10549-026-08019-y

Authors (22)

Binliang Liu, Tao Wu, Sijuan Ding, Xuan Liu, Xiaochun Zeng, Ziru Liu, Kaili Lu, Jiantao She, Jun Chen, Heng Tian, Qin Tong, Ke Tang, Juan Yu, Jianguo Wang, Li Ding, Yan Li, Liping Peng, Qiang Zhou, Huichong Zhou, Tengfei Chao, Quchang Ouyang, Ning Xie

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Liu, B., Wu, T., Ding, S., et al. (2026). Machine learning and cox model–based prediction of CDK4/6 inhibitor outcomes in HR+/HER2 − metastatic breast cancer: a multicenter real-world study. Breast Cancer Research and Treatment. https://doi.org/10.1007/s10549-026-08019-y

Related articles

• Clinical Outcomes of HER2‐Low Versus HER2‐Zero in HR‐Positive Metastatic Breast Cancer Treated With Endocrine Therapy With or Without CDK4/6 Inhibitors: A Multicenter Retrospective Study · International Journal of Breast Cancer · 2025 · Cites or is cited by this article
• Retrospective study on regional nodal irradiation after omission of axillary lymph node dissection in sentinel lymph node-positive breast cancer: a propensity score matching analysis · Breast Cancer Research and Treatment · 2026 · Same journal
• Factors influencing discussion duration in breast cancer multidisciplinary team meetings: insights for streamlining care · Breast Cancer Research and Treatment · 2026 · Same journal
• Antacid co-treatment and pregnane X receptor genetic polymorphisms are survival determinants in patients treated with palbociclib · Breast Cancer Research and Treatment · 2026 · Same journal
• Curative-intent stereotactic ablative body radiation, surgery, and systemic therapy in non-osseous oligometastatic breast cancer · Breast Cancer Research and Treatment · 2026 · Same journal
• Early first-line systemic anticancer therapeutic attrition after metastatic recurrence in triple-negative breast cancer following neoadjuvant chemo-immunotherapy: a multicenter real-world study · Breast Cancer Research and Treatment · 2026 · Same journal
• Abemaciclib rechallenge after progression on abemaciclib plus endocrine therapy in patients with hormone receptor-positive HER2-negative metastatic breast cancer: results from the phase II again study (WJOG14220B) · Breast Cancer Research and Treatment · 2026 · Same journal
• Age-stratified difference in patient-reported health-related quality of life following breast cancer surgery · Breast Cancer Research and Treatment · 2026 · Same journal
• Rediscovering the Ciucci pathway: in-vivo evidence of a palmar lymphatic channel · Breast Cancer Research and Treatment · 2026 · Same journal
• Clinical implications of discordance in HER2 reassessment from HercepTest to 4B5 in metastatic breast cancer · Breast Cancer Research and Treatment · 2026 · Same journal